Skip to contentB
Biogen Inc.
B
BIIBBiogen Inc. Q3 2013 · 10-Q
Revenue$1.83B$1.83B+31.9% vs Q3 2012 Net Income$487.60M$487.60M+22.4% vs Q3 2012 EPS Diluted$2.05$2.05+22.8% vs Q3 2012 Gross Profit$1,593,100,000+27.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
Operating Cash Flowderived$671,922,000+24.0% Free Cash Flowderived$591,734,000+22.3% Margins · derivedGross margin87.2%−2.8 pt vs Q3 2012
Operating margin37.5%−1.2 pt vs Q3 2012
Net margin26.7%−2.1 pt vs Q3 2012
ended Sep 30, 2013 · filed Oct 28, 2013 · 28 d after period end